Quantcast

Latest Applied genetics Stories

2010-05-11 11:00:00

PARIS, May 11 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis' approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010. Targeted approaches have emerged today as an...

2010-04-20 00:00:00

ST. LOUIS, April 20 /PRNewswire-FirstCall/ -- Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich® (Nasdaq: SIAL), today announced an extension to its award-winning CompoZr® product offering with the global release of the CompoZr Targeted Integration Kit, AAVS1 (www.sigma.com/aavs1). This kit provides a powerful method for the controlled transgene integration and expression of any gene in any...

2010-04-06 08:38:34

Novel therapy for blindness works only when specific gene mutation present Leber congenital amaurosis (LCA) is a congenital retinal dystrophy present in approximately 1 of 80,000 births. It is estimated that about 3,000 people in the United States are living with LCA and will likely become blind in their lifetimes. Recently, there has been progress in gene therapy for this condition. In a recent study published in the current issue of the Journal of AAPOS, the Official Publication of the...

2010-03-10 00:57:00

AMSTERDAM, March 10, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease. The trial is an open label dose-escalation study using a vector-gene combination developed at the renowned St. Jude Children's Research...

d8330c707df3fe09726dcf99036c2b3e
2010-03-03 14:18:12

Results bode well for treating people with the disease Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle. The same research team that conducted the human trial now reports that a study in animals has shown that a second injection of genes into the opposite, previously untreated eye is safe and effective, with no signs of interference from...

2010-01-25 00:00:00

AMSTERDAM, The Netherlands, January 25 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD). The submission of the Glybera(R) Marketing Authorisation Application (MAA), announced earlier, has cleared the validation stage with The...

2010-01-08 15:54:54

Tag-team Approach Breaks the Size Barrier for Gene Therapy Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system. The team has brought together the herpes virus and a molecule known as Sleeping Beauty to improve a technology known as gene therapy, which aims to manipulate genes to correct for molecular flaws that cause disease. The work, detailed in a paper published online in Gene Therapy, has allowed scientists at the...

2009-12-02 00:00:00

AMSTERDAM, December 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a number of management changes. Piers Morgan (age 43) has been appointed Chief Financial Officer, effective December 1, 2009. Hans Preusting, PhD (age 47), Director Process Development & Manufacturing, will take up the responsibility for Operations and Project Management, also effective December 1. These changes reflect the...

2009-10-26 15:30:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Direct-To-Consumer Genetic Testing: Business Prospects in the United States http://www.reportlinker.com/p0156564/Reportlinker-Adds-Direct-To-Consumer-Genetic-Testing-Business-Prospects-in-the-United-States.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire The current marketplace for direct-to-consumer (DTC) genetic testing...

2009-10-07 08:25:28

Kids' right-to-privacy for their genetic material needs better protection, says Tel Aviv University researcher Scientists look for clues about therapies and cures for life-threatening childhood illnesses in children's DNA "” it seems only logical to do so. But the decision as to who should have access to DNA samples from children provides a unique ethical conundrum, says a Tel Aviv University researcher in a recent publication for the esteemed journal Science, co-authored by...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related